ARHGAP45 Polyclonal Antibody

Cat.#: 160498

Special Price 174.2 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    ARHGAP45 Polyclonal Antibody
  • Documents
  • Description
    Polyclonal antibody to ARHGAP45
  • Tested applications
    WB
  • Species reactivity
    Human, Rat
  • Alternative names
    ARHGAP45 antibody; HA-1 antibody; HLA-HA1 antibody; HMHA1 antibody; Rho GTPase activating protein 45 antibody
  • Isotype
    Rabbit IgG
  • Preparation
    Antigen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-160 of human ARHGAP45 (NP_036424.2).
  • Clonality
    Polyclonal
  • Formulation
    PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
  • Storage instructions
    Store at -20℃. Avoid freeze / thaw cycles.
  • Applications
    WB 1:500 - 1:2000
  • Validations

    Western blot - ARHGAP45 Polyclonal Antibody

    Western blot - ARHGAP45 Polyclonal Antibody

    Western blot analysis of extracts of various cell lines, using ARHGAP45 antibody at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit .Exposure time: 30s.

  • Background
    Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity.; Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"